Molecular biology progress of small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
; (12): 115-118, 2018.
Article
em Zh
| WPRIM
| ID: wpr-693457
Biblioteca responsável:
WPRO
ABSTRACT
Small cell lung cancer (SCLC) is typified by early recurrence and metastasis associated with many genetic changes.The drug ROVA-T composed of the DLL3 antibody Rovalpituzumab and the cytotoxic drug Tesirine achieves the tumor-killing effect by releasing the Tesirine when bound to DLL3.Nfib promotes the SCLC metastasis by altering the structure of the chromosome.The PRAP,EZH2 and Weel inhibitors inhibit the DNA damage repair to improve the antitumor activity of chemotherapeutic drugs.Combination of Ipilimumab and Nivolumab can activate the human immune system to exert antitumor effect.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of International Oncology
Ano de publicação:
2018
Tipo de documento:
Article